Atlanta, September 25th – Neuronostics’ have won a prize of $125,000 to support the further development of their patented Software-as-a-Medical-Device BioEP™. BioEP is a ground-breaking clinical decision support tool that can provide an objective rating of the level of support for a diagnosis of epilepsy using clinical data that is currently considered uninformative.
BioEP uses the power of mathematical modelling to interrogate recordings of the brain’s electrical activity (EEG) that are routinely collected from people who are suspected of having epilepsy. In over 70% of cases the test is clinically inconclusive resulting in delays, uncertainty and cost, as well as have a significant impact on quality of life for people with suspected epilepsy. BioEP can address some of these challenges, providing additional information to help prioritise workload, determine most appropriate next steps and impact confidence in clinical decision-making.
Inspired by the American equivalent of Dragon’s Den, the Epilepsy Foundation Shark Tank competition attracts entrepreneurs, scientists, and clinicians from around the world who are developing novel approaches to address the challenges of epilepsy. Four other finalists from Portugal, France and the US competed alongside Neuronostics from a pool of approaching 50 applicants.
5 Sharks representing clinicians, venture capital and the patient voice grilled each team on the science behind their ideas and their commercial plan, as well as the potential of the technology to meaningfully impact people with epilepsy and their families. Each Shark got to award $25,000, with a vote from the watching audience determining a further $75,000 in prize money. Following an animated debate, Neuronostics secured the support of 2 Sharks as well as taking the audience vote to secure total prize money of $125,000.
John Terry, Co-Founder and Managing Director of Neuronostics who pitched BioEP in the competition said afterwards “We are delighted to have received this recognition from the Epilepsy Foundation.
“Having regulated BioEP with the MHRA, we are excited to bring the product to the NHS during 2025. This win further demonstrates the potential for BioEP to meaningfully benefit the 500,000 Americans who are suspected of having epilepsy each and every year.
“Speaking with many attendees afterwards it was clear that our pitch had made waves and it was fantastic that we got a couple of sharks to bite!”
“Receiving an award at Shark Tank isn’t just about the prize,” said Caitlin Grzeskowiak, vice president research and innovation, Epilepsy Foundation. “It’s a testament to Neuronostics team to showcase these significant technological advancements past what currently exists for the epilepsy community. We are incredibly proud of what they’ve accomplished and look forward to continued collaboration. I know this technology can make a real difference for many living with epilepsy.”
Neuronostics plans to use the prize funding to accelerate the development of its technology, with the goal of securing approval from the US Food and Drug Administration (FDA) that will enable the launch of BioEP in the US market during 2026.
Read more here.
About Neuronostics
Neuronostics is a healthcare technology company specializing in the development of novel digital solutions for the diagnosis and management of neurological conditions. By combining advanced computational modelling with machine learning, Neuronostics aims to deliver rapid, accessible, and accurate assessments of brain activity, improving outcomes for patients with conditions like epilepsy.
About the Epilepsy Foundation
With a network of partners throughout the United States, the Epilepsy Foundation is leading the fight to overcome the challenges of living with epilepsy. The Foundation connects people to treatment, support, and resources; leads advocacy efforts; funds innovative research and the training of specialists; and educates the public about epilepsy and seizure first aid. For more than five decades, the Epilepsy Foundation has shone a light on epilepsy to promote awareness and understanding, and to advocate for laws that matter to people with epilepsy, while also funding epilepsy research and supporting epilepsy investigators and specialists in their early careers. In partnership with the CDC, the Epilepsy Foundation has helped to improve access to care for people with epilepsy, expanded its digital reach and online resources in homes across the country, and trained more than 600,000 people in seizure recognition and first aid. The Epilepsy Foundation continues to focus on serving the epilepsy community through advocacy, education, direct services, and research for new therapies. To learn more visit epilepsy.com or call 1.800.332.1000; in Spanish at 866.748.8008 or laepilepsia.org. Follow us on Facebook, Instagram, Twitter, LinkedIn, TikTok and YouTube.
